Why CEO AstraZeneca believes the pharmaceutical company can almost double revenues by 2030
In a Tuesday interview with CNBC's Jim Cramer, AstraZeneca CEO Pascal Soriot explained why the drug maker believes it can almost double revenues by the end of the decade. AstraZeneca announced in l...
Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
In the latest trading session, Astrazeneca (AZN) closed at $78.99, marking a +1.24% move from the previous day.
TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer v...
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the LAURA Phase III trial showed AstraZeneca's TAGRISSO® (osimertinib) demonstrated a statistically significant and highly clinically meanin...
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III tria...
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the ADRIATIC Phase III trial showed AstraZeneca's IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful imp...
AstraZeneca started at buy at Goldman, which rates GSK a neutral
Goldman Sachs started coverage of AstraZeneca at buy as it rated rival pharmaceutical company GSK a neutral.
AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock
AstraZeneca's newly-announced ambitions point to big growth ahead. At the same time, Pfizer's strategy is also proving quite ambitious.
AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock?
AstraZeneca just wrapped up its last strategic plan successfully. It's now setting a new ambition to be completed by 2030.
AstraZeneca Rises to Record High After Announcing Plans for 'New Era of Growth'
AstraZeneca's (AZN) American depositary receipts (ADRs) rose over 2% to a record high Tuesday after the Anglo-Swedish drug maker announced what it called its “bold ambition” for future growth.
AstraZeneca's new 2030 targets are bold attempt to reach for the stars, say analysts
After AstraZeneca PLC (LSE:AZN) unveiled new sales and profit targets for the end of the decade, analysts were mildly impressed by the ambition to "shoot for the stars". Starting with the bare numb...
AstraZeneca targets $80 billion in total revenue by 2030 with release of 20 new medicines
Pharmaceutical company AstraZeneca is planning to increase its total revenue by 75% and release 20 new medicines by 2030, including cancer treatments.
AstraZeneca kicks off ‘new era of growth' with aim to hit $80 billion of sales by 2030
AstraZeneca on Tuesday outlined ambitions to almost double its sales over the next six years by launching 20 new medicines by 2030.
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030
CAMBRIDGE, England--(BUSINESS WIRE)--Investor Day 2024.
AstraZeneca (AZN) to Build $1.5B Cancer Drug Plant in Singapore
This new plant will be AstraZeneca's (AZN) first manufacturing facility for producing novel antibody drug conjugates from start to finish. It is scheduled to open in 2029.
AstraZeneca plans to build $1.5 bln manufacturing facility in Singapore
AstraZeneca is planning to build a $1.5 billion manufacturing facility in Singapore in an effort to enhance its antibody drug conjugates (ADCs) portfolio, the drugmaker said on Monday.
AstraZeneca's investigational COVID drug meets primary goals in late-stage study
AstraZeneca said on Thursday its investigational drug, sipavibart, met primary goals in preventing COVID-19 in immunocompromised patients in a late-stage trial.
Related Companies